Optus Pharmaceutical

옵투스제약 · 131030

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$77.9M (₩107.5B)

Overview

Optus Pharmaceutical makes prescription and over-the-counter eye drops, including preservative-free single-use vials, used to treat dry eye, glaucoma, and allergic conditions.

Listed on KOSDAQ, Korea's tech and small-cap board, it supplies hospitals and clinics directly and also manufactures eye drops on behalf of other pharmaceutical companies under contract development and manufacturing arrangements. Its business spans four segments: a prescription ophthalmology unit, a contract manufacturing unit, an export-focused global unit, and a consumer eye-care brand called OUE&.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$63.2M
▲ +6.4% YoY
Operating profit · FY2025
US$6.4M
▲ +3.3% YoY
Net income · FY2025
US$8.2M
▲ +10.2% YoY

Revenue

  • FY2023US$52.5M
  • FY2024US$59.4M
  • FY2025US$63.2M

Operating profit

  • FY2023US$5.9M
  • FY2024US$6.2M
  • FY2025US$6.4M

Net income

  • FY2023US$7.8M
  • FY2024US$7.5M
  • FY2025US$8.2M

Key ratios (FY2025)

ROE
6.9%
Debt/Eq
15.8%
Op. margin
10.2%
Net margin
13.0%
Rev. YoY
▲ +6.4%

Why it matters

The company operates its own production facility in the Osong Life Science Industrial Complex in Chungcheongbuk-do and a central research institute in Suwon, giving it in-house manufacturing and R&D capabilities.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.